v3.26.1
Segment Information - Reportable Segment Information (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Net sales $ 1,954 $ 1,919 $ 3,860 $ 3,969
Cost of sales (1,101) (1,095) (2,178) (2,293)
Research & development expenses (170) (170) (324) (325)
Selling & administrative expenses (437) (409) (771) (799)
Adjusted Operating EBITDA   399 841 843
Depreciation & Amortization (154) (146) (306) (288)
Interest Expense (46) (61) (90) (132)
Other expense, net (20) (20) (33) (39)
Restructuring Charges (6) (20) (10) (35)
Impairment 0 0 0 (34)
Losses on business disposals (1) (111) (1) (111)
Loss on held for sale classification (27)   (27)  
Divestiture And Integration Costs (10) (26) (15) (77)
Strategic initiative costs (9) (6) (18) (14)
Regulatory costs (71) (53) (81) (64)
Gain (loss) on extinguishment of debt 0 488 0 488
Tax realignment costs (1) (4) (2) (5)
Other gains (losses) 1 (2) 2 (6)
Income from continuing operations before taxes 64 438 260 526
Segment capital expenditures 98 63 233 208
Taste        
Segment Reporting [Line Items]        
Restructuring Charges (3) (8) (5) (10)
Health & Biosciences        
Segment Reporting [Line Items]        
Restructuring Charges (3) (7) (5) (11)
Scent        
Segment Reporting [Line Items]        
Restructuring Charges 0 (5) 0 (14)
Operating Segments        
Segment Reporting [Line Items]        
Net sales 1,954 1,919 3,860 3,969
Adjusted Operating EBITDA from Continuing Operations 408 399 841 843
Operating Segments | Taste        
Segment Reporting [Line Items]        
Net sales 688 654 1,368 1,304
Cost of sales (415) (397) (808) (791)
Research & development expenses (48) (49) (93) (90)
Selling & administrative expenses (120) (108) (228) (209)
Depreciation expense add-back (a) 19 17 37 32
Adjusted Operating EBITDA from Continuing Operations 124 117 276 246
Segment capital expenditures 33 15 67 56
Operating Segments | Health & Biosciences        
Segment Reporting [Line Items]        
Net sales 601 559 1,176 1,079
Cost of sales (313) (294) (622) (576)
Research & development expenses (58) (55) (111) (106)
Selling & administrative expenses (114) (101) (219) (193)
Depreciation expense add-back (a) 34 30 66 58
Adjusted Operating EBITDA from Continuing Operations 150 139 290 262
Operating Segments | Scent        
Segment Reporting [Line Items]        
Net sales 665 603 1,316 1,217
Cost of sales (374) (336) (749) (679)
Research & development expenses (64) (62) (120) (120)
Selling & administrative expenses (112) (101) (209) (191)
Depreciation expense add-back (a) (19) (17) (37) (32)
Adjusted Operating EBITDA from Continuing Operations 134 121 275 259
Segment capital expenditures 20 12 69 53
Operating Segments | Pharma Solutions        
Segment Reporting [Line Items]        
Net sales   103   369
Cost of sales   (68)   (248)
Research & development expenses   (3)   (8)
Selling & administrative expenses   (10)   (42)
Depreciation expense add-back (a)   0   (5)
Adjusted Operating EBITDA from Continuing Operations   22   76
Segment capital expenditures 0 10 0 38
Operating Segments | Health And Biosciences        
Segment Reporting [Line Items]        
Segment capital expenditures $ 45 $ 26 $ 97 $ 61